88 terminated. 88 Phase 2, 35 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 88 | Terminated 88 |
| Phase 1 | 35 | Terminated 35 |
| Phase 3 | 1 | Terminated 1 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer PCS6422 and capecitabine, Capecitabine - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Terminated | Processa Pharmaceuticals | 20 | 2024-10-02 | 2026-10-06 |
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer Atezolizumab + RP1 - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | Institut Curie | 2 | 2024-04-05 | 2025-06-11 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| PRO1107 in Patients With Advanced Solid Tumors GEN1107 - Endometrial Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 33 | 2024-01-03 | 2026-10-29 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Bemarituzumab - Solid Tumors | Phase 1 / Phase 2 | Terminated | Amgen | 260 | 2022-09-23 | 2026-06-22 |
| Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients SKL27969 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | SK Life Science, Inc. | 15 | 2022-09-12 | 2025-05-04 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer Deferoxamine Plus Chemotherapy - Triple Negative Breast Cancer | Phase 2 | Terminated | Sun Yat-sen University | 25 | 2022-03-21 | 2025-07-22 |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy Atezolizumab Injection, Bevacizumab, Pertuzumab - Breast Cancer | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 33 | 2022-02-24 | 2025-12-01 |
| RTX-224 Monotherapy in Patients With Solid Tumors RTX-224 - Non Small Cell Lung Cancer, Cutaneous Melanoma | Phase 1 / Phase 2 | Terminated | Rubius Therapeutics | 7 | 2022-01-12 | 2022-12-09 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer Magrolimab, Nab-Paclitaxel, Paclitaxel - Triple-Negative Breast Cancer | Phase 2 | Terminated | Gilead Sciences | 92 | 2021-12-14 | 2025-11-04 |
| Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer Trilaciclib, Sacituzumab Govitecan-hziy - Triple Negative Breast Cancer | Phase 2 | Terminated | G1 Therapeutics, Inc. | 30 | 2021-12-08 | 2025-01-29 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer vidutolimod, cemiplimab - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 2 | Terminated | Regeneron Pharmaceuticals | 77 | 2021-11-30 | 2026-06-09 |
| A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC Chiauranib, capecitabine - Triple-negative Breast Cancer | Phase 2 | Terminated | Chipscreen Biosciences, Ltd. | 9 | 2021-11-05 | 2025-03-24 |
| A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer Talazoparib, Atezolizumab, Radiation - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Terminated | Mylin A. Torres, MD | 1 | 2021-10-04 | 2023-12-04 |
| Olinvacimab With Pembrolizumab in Patients With mTNBC Olinvacimab - Metastatic Triple-Negative Breast Cancer | Phase 2 | Terminated | PharmAbcine | 19 | 2021-09-30 | 2025-12-30 |
| Sitravatinib in Metastatic Breast Cancer Sitravatinib - Breast Cancer Stage IV, Triple Negative Breast Cancer | Phase 2 | Terminated | Xiang Zhang | 3 | 2021-09-22 | 2024-08-26 |
| Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer Capecitabine, Talazoparib, Pembrolizumab - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Terminated | Bryan Schneider, MD | 52 | 2021-08-24 | 2025-05-31 |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Fruquintinib, Tislelizumab - Triple Negative Breast Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 52 | 2021-08-09 | 2025-07-14 |
Showing 20 of 88. Sign in to see all of them.
Breast Neoplasms (35) · Carcinoma, Non-Small-Cell Lung (20) · Neoplasm Metastasis (13) · Squamous Cell Carcinoma of Head and Neck (13) · Melanoma (11) · Carcinoma, Renal Cell (9) · Carcinoma, Transitional Cell (8) · Ovarian Neoplasms (8) · Stomach Neoplasms (7) · Colorectal Neoplasms (6) · Carcinoma, Merkel Cell (5) · Pancreatic Neoplasms (5) · Carcinoma, Hepatocellular (4) · Endometrial Neoplasms (4)
Breast Diseases (88) · Neoplasms by Site (88) · Skin Diseases (88) · Skin and Connective Tissue Diseases (88) · Neoplasms (84) · Breast Neoplasms (53) · Neoplasms by Histologic Type (28) · Neoplasms, Glandular and Epithelial (27) · Carcinoma (24) · Respiratory Tract Neoplasms (21) · Thoracic Neoplasms (21) · Bronchial Neoplasms (20) · Carcinoma, Bronchogenic (20) · Lung Diseases (20) · Respiratory Tract Diseases (20)
Carboplatin (11) · pembrolizumab (11) · Cyclophosphamide (7) · atezolizumab (7) · Capecitabine (6) · Paclitaxel (6) · Albumin-Bound Paclitaxel (5) · Cisplatin (4) · Gemcitabine (4) · Nivolumab (4) · talazoparib (4) · 130-nm albumin-bound paclitaxel (3) · Docetaxel (3) · avelumab (3) · sacituzumab govitecan (3)
Genmab (3) · M.D. Anderson Cancer Center (3) · Pfizer (3) · Sun Yat-sen University (3) · University of Wisconsin, Madison (3) · G1 Therapeutics, Inc. (2) · National Cancer Institute (NCI) (2) · Vanderbilt-Ingram Cancer Center (2) · Washington University School of Medicine (2) · AVEO Pharmaceuticals, Inc. (1) · Amgen (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Ayala Pharmaceuticals, Inc, (1) · Barbara Ann Karmanos Cancer Institute (1) · BerGenBio ASA (1)
United States (65) · Spain (16) · France (10) · United Kingdom (10) · Belgium (9) · Italy (9) · Australia (8) · Canada (8) · China (8) · Taiwan (7) · Poland (6) · South Korea (6) · Hungary (5) · Japan (5) · Germany (4)
Kari Wisinski, MD (2) · Amy Weise, M.D. (1) · Andres Gutierrez, MD, PhD (1) · Andrew Davis, M.D. (1) · Andrew S Poklepovic, MD (1) · Ashley Ward, M.D. (1) · Brenton Seidl, Ph.D, MD (1) · Bryan P Schneider, MD (1) · C. Kent Osborne, MD (1) · Carlos H Barcenas (1) · Claire Beecroft, Ph.D, MD (1)
PMID 26059540, PMID 30400780, PMID 32379297, PMID 34173924, PMID 34385584, PMID 34398557, PMID 35414025, PMID 35444059, PMID 36879012, PMID 37046691, PMID 39038917, PMID 40762544, PMID 41405563, PMID 41424175, PMID 42259602
2016 (4), 2018 (4), 2019 (3), 2017 (2), 2023 (2), 2008 (1), 2014 (1), 2015 (1), N01CM00032 (1), N01CM62204 (1), P01CA234212 (1), P30CA013330 (1), P30CA022453 (1), P30CA068485 (1), R01CA193004 (1)